Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P71 - Tumor Biology and Systems Biology - Basic and Translational Science - RTK/VEGF
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
P71.01 - The Effects of Vascular Endothelial Cells on Regulating Post-Irradiation Microglia Phenotype in Irradiation-Induced Brain Injury
00:00 - 00:00 | Presenter: Jiaojiao Wang
- Abstract
Loading... -
+
P71.02 - Estrogen Promotes Resistance to Bevacizumab Treatment in Non-Small Cell Lung Cancer (NSCLC) Xenograft Models
00:00 - 00:00 | Presenter: Sonia A Patel
- Abstract
Loading...
-
+
P72 - Tumor Biology and Systems Biology - Basic and Translational Science - Tumor Microenvironment
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
P72.01 - Stress-Induced Upregulation of TNFSF4 in Cancer Associated Fibroblasts Facilitates Chemoresistance of Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Yan Li
- Abstract
Loading... -
+
P72.02 - Cellular Landscape of Tumor Immune Microenvironment and Genetic Signatures Identify Prognostic of LUAD
00:00 - 00:00 | Presenter: Si-Yang Liu
- Abstract
Loading... -
+
P72.03 - Tumor Microenvironment Disparity in Multiple Primary Lung Cancers
00:00 - 00:00 | Presenter: Motohiro Izumi
- Abstract
Loading... -
+
P72.04 - Statin Counteracts Cell Proliferation and EMT-Induction in NCI-H322M Cells Treated with TGF-β
00:00 - 00:00 | Presenter: Katsuhiko Warita
- Abstract
Loading... -
+
P72.05 - From OR to Lab: Optimized Protocol for Functional Immune Profiling of Freshly Resected Human Non-Small Cell Lung Carcinoma (NSCLC) Specimens
00:00 - 00:00 | Presenter: Sylvia Vania Alarcon
- Abstract
Loading... -
+
P72.06 - NLRP4-Mediated Type I Interferon Response Benefits Immune Checkpoint Therapy Through Redirecting CD8+ T Cell Distribution in TME
00:00 - 00:00 | Presenter: Liliang Xia
- Abstract
Loading... -
+
P72.07 - Modulation of the Tumor Microenvironment by Targeting ERb/HER Oncogenic Network in Lung Cancer Produces Synergy when Followed by Immunotherapy
00:00 - 00:00 | Presenter: Abdulaziz Abdullah Almotlak
- Abstract
Loading... -
+
P72.08 - Overexpression of LINC00942 is Associated With a Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Jie Yang
- Abstract
Loading... -
+
P72.09 - Study of Relationship Between Proportion of CTLA-4 Positive Tregs in Tumor Infiltrating Lymphocytes and PD-L1 TPS
00:00 - 00:00 | Presenter: Satoshi Muto
- Abstract
Loading... -
+
P72.10 - Prognostic Significance of IgA+ B Cells in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Marie Vanderputten
- Abstract
Loading...
-
+
P73 - Tumor Biology and Systems Biology - Basic and Translational Science - RTK/FGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
P73.01 - Clinicopathologic Characteristics and Survival Outcome in East Asian Patients With Non-Small Cell Lung Cancer and FGFR2 Mutations
00:00 - 00:00 | Presenter: Chun-wei Xu
- Abstract
Loading... -
+
P73.02 - The Landscape of FGFR Alteration in Chinese Patients with Lung Cancer
00:00 - 00:00 | Presenter: Huilin Wang
- Abstract
Loading... -
+
P73.03 - A Kinome CRISPR Screen in FGFR-Amplified Lung Cancer
00:00 - 00:00 | Presenter: Zhang Yang
- Abstract
Loading...
-
+
P74 - Health Services Research/Health Economics - Real World Evidence
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P74.01 - Barries in Precision Medicine Implementation Among Advanced Nonsquamous Cell Lung Cancer-Patients: A Real-World Scenario
00:00 - 00:00 | Presenter: Flavia Amaral Duarte
- Abstract
Loading... -
+
P74.02 - Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network
00:00 - 00:00 | Presenter: Julia Roeper
- Abstract
Loading...
-
+
P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P75.01 - Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial
00:00 - 00:00 | Presenter: Toyoaki Hida
- Abstract
Loading... -
+
P75.02 - Non-Squamous NSCLC Patients Harbored STK11 or KEAP1 Mutation Showed Insensitivity to any Treatment Including Immunotherapy
00:00 - 00:00 | Presenter: Haiyong Wang
- Abstract
Loading... -
+
P75.03 - KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC
00:00 - 00:00 | Presenter: Suman Rao
- Abstract
Loading... -
+
P75.04 - Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC
00:00 - 00:00 | Presenter: Petros Christopoulos
- Abstract
Loading... -
+
P75.05 - Integrative Modeling of Tumor Burden and Metastatic Pattern for Second-Line anti-PD-L1 Therapy of Non–Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Si-Cong Ma
- Abstract
Loading... -
+
P75.06 - Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases
00:00 - 23:59 | Presenter: Shinkichi Takamori
- Abstract
Loading... -
+
P75.07 - Association of FGFR4 Mutation With Immunotherapy Outcomes in Patients With Cancer
00:00 - 00:00 | Presenter: Lingshuang Liu
- Abstract
Loading... -
+
P75.08 - KDM5C Mutation Is Associated with Better Immunotherapy Outcomes in Non–Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Kun Wang
- Abstract
Loading... -
+
P75.09 - Analysis of Immune Microenvironment and Prognosis of NSCLC Patients Harbored SMARCA4 Mutation
00:00 - 00:00 | Presenter: Haiyong Wang
- Abstract
Loading... -
+
P75.10 - Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients
00:00 - 00:00 | Presenter: Yiqing Huang
- Abstract
Loading... -
+
P75.11 - Potential Predictive Value of TERT Mutation Status for Response to Immunotherapy in Cancer Patients
00:00 - 00:00 | Presenter: Xiangyun Wang
- Abstract
Loading... -
+
P75.12 - Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy
00:00 - 00:00 | Presenter: Nitya Surya
- Abstract
Loading... -
+
P75.13 - Hyperprogressive Disease in Non-Small Cell Lung Cancer on pd-1 Inhibitor.
00:00 - 00:00 | Presenter: Tae-Won Jang
- Abstract
Loading... -
+
P75.14 - Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience
00:00 - 00:00 | Presenter: Domenico Galetta
- Abstract
Loading... -
+
P75.15 - Predictive Factors of Survival in Non-Small Cell Lung Cancer Patients Without Durable Response to PD-1/L1 Inhibitors
00:00 - 00:00 | Presenter: Yuhei Harutani
- Abstract
Loading... -
+
P75.16 - Real-World Data from a Spanish Institution
00:00 - 00:00 | Presenter: Inmaculada Ramos
- Abstract
Loading... -
+
P75.17 - Baseline D-Dimer Levels Predict Prognosis in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
00:00 - 00:00 | Presenter: Jinliang Wang
- Abstract
Loading... -
+
P75.18 - Association of the LIPI With Survival and Response in Advanced NSCLC Patients Treated With Immune Checkpoint Inhibitors
00:00 - 00:00 | Presenter: Jinliang Wang
- Abstract
Loading... -
+
P75.19 - Investigation of Lung Cancer Patients Receiving Immunotherapy with Pre-Existing Lung Disease
00:00 - 00:00 | Presenter: Kerri McGovern
- Abstract
Loading... -
+
P75.20 - Outcomes of Lung Cancer Patients with Leptomeningeal Metastases Following Immune Checkpoint Inhibitor Treatments: A Pooled Analysis
00:00 - 00:00 | Presenter: meimei Zheng
- Abstract
Loading... -
+
P75.21 - Impact of Diagnosis and Treatment of Concurrent Infections during Immunotherapy in Advanced Lung Cancer: A Retrospective Cohort Study
00:00 - 00:00 | Presenter: Domenico Galetta
- Abstract
Loading... -
+
P75.22 - Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
00:00 - 00:00 | Presenter: Kewei Ma
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.01 - Impact of Clinicopathological Features on Efficacy of Osimertinib in Advanced NSCLC Patients With EGFR Mutations
00:00 - 00:00 | Presenter: Yubo Wang
- Abstract
Loading... -
+
P76.02 - Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor
00:00 - 00:00 | Presenter: Chun-wei Xu
- Abstract
Loading... -
+
P76.03 - Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Enriqueta Felip
- Abstract
Loading... -
+
P76.04 - Prospective Study on Molecular Biomarkers in Advanced Lung Adenocarcinoma and Predilection for EGFR Mutation with Metastatic Sites
00:00 - 00:00 | Presenter: Mohanakrishnan Jayamani
- Abstract
Loading... -
+
P76.05 - Radiotherapy with Concurrent Versus Sequential Osimertinib for Advanced Non-Small Cell Lung Cancer: a Multi-Center Toxicity Analysis
00:00 - 00:00 | Presenter: David C. Qian
- Abstract
Loading... -
+
P76.06 - A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Dong Shen
- Abstract
Loading... -
+
P76.07 - Metformin Enhances the Efficacy of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients With Type 2 Diabetes Mellitus
00:00 - 00:00 | Presenter: Ruoshuang Han
- Abstract
Loading... -
+
P76.08 - High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs
00:00 - 00:00 | Presenter: Jia Liu
- Abstract
Loading... -
+
P76.09 - A Comparison of Sequential EGFR-TKI Therapy Versus First-Line Osimertinib in NSCLC: A Multi-Center, Retrospective Study
00:00 - 00:00 | Presenter: Chung-Shien Lee
- Abstract
Loading... -
+
P76.10 - Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
00:00 - 00:00 | Presenter: Tianqing Chu
- Abstract
Loading... -
+
P76.100 - Primary Drug Resistance to EGFR-TKIs by EGFR p.V1010M Germline Mutation Combined with EGFR p.L858R Somatic Mutation and its Pedigree Analysis
00:00 - 00:00 | Presenter: Youfan Jiang
- Abstract
Loading... -
+
P76.11 - Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Mutated NSCLC
00:00 - 00:00 | Presenter: Sangtian Liu
- Abstract
Loading... -
+
P76.12 - Impact of Inflammatory Markers and Body Mass Index on TKI Toxicity in Patients With Non-Small Cell Lung Cancer Harboring an EGFR Mutation
00:00 - 00:00 | Presenter: Thanya Runciman
- Abstract
Loading... -
+
P76.13 - Osimertinib Delays but Not Prevents Central Nervous System Metastasis in EGFR-Mutant Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jianjiao Ni
- Abstract
Loading... -
+
P76.14 - Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI + Brain Radiation
00:00 - 00:00 | Presenter: Nicholas Joseph Thomas
- Abstract
Loading... -
+
P76.15 - Osimertinib Improved Overall Survival in mEGFR NSCLC Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status
00:00 - 00:00 | Presenter: Jiyun Lee
- Abstract
Loading... -
+
P76.16 - EGFR-L858R NSCLC with Pleiotropic Resistance Mechanisms: T790M, C797S, SCLC-Transformation and KRAS, TP53, and BRAF Mutations.
00:00 - 00:00 | Presenter: Edyta Maria Urbanska
- Abstract
Loading... -
+
P76.17 - Prognostic Role of the Systemic Immune-Inflammatory Index (SII) in Driver-Mutation Positive NSCLC: Real-World EGFR-Mutant Disease
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading... -
+
P76.18 - Tissue- and Plasma-Based Landscape of Resistance to Osimertinib
00:00 - 00:00 | Presenter: Sun Min Lim
- Abstract
Loading... -
+
P76.19 - Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib
00:00 - 00:00 | Presenter: Chang Lu
- Abstract
Loading... -
+
P76.20 - The Predictive Values of Non-Resistant Nncommon EGFR Mutations in Advanced Non-Small Cell Lung Cancer Patients
00:00 - 00:00 | Presenter: Peng-Bo Deng
- Abstract
Loading... -
+
P76.21 - EGFR-KDD with Duplication of Exons 18-26 Responding to Afatinib Treatment in a Patient with Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Yiying Qian
- Abstract
Loading... -
+
P76.22 - Acquired an EGFR Amplification in EGFR Exon 20 insertion Lung Adenocarcinoma Resistant to First Line Osimertinib Treatment
00:00 - 00:00 | Presenter: Chengwei Zhou
- Abstract
Loading... -
+
P76.23 - A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors
00:00 - 00:00 | Presenter: SHO Mitsuya
- Abstract
Loading... -
+
P76.24 - A Randomized Phase 2 Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-Line Therapy for EGFR-Negative NSCLC (ALTER-L018)
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P76.25 - Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKI and Once-Daily Thoracic RT: Predicting Values of Clinical and DVH Parameters
00:00 - 00:00 | Presenter: Xuexi Yang
- Abstract
Loading... -
+
P76.26 - Survival Outcomes in Patients Receiving Second Line Osimertinib Post First Line First Generation TKI Alone or in Combination with Chemotherapy
00:00 - 00:00 | Presenter: Satvik Khaddar
- Abstract
Loading... -
+
P76.27 - ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
P76.28 - Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
00:00 - 00:00 | Presenter: Pingli Wang
- Abstract
Loading... -
+
P76.29 - Clinical Observation of EGFR-TKI Combined With 89Sr in the Treatment of Non-Small Cell Lung Cancer With Osteoblastic Reaction
00:00 - 00:00 | Presenter: Yu-ming Jia
- Abstract
Loading... -
+
P76.30 - The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with EGFR Mutated Advanced NSCLC
00:00 - 00:00 | Presenter: Sherin Rouhani
- Abstract
Loading... -
+
P76.31 - Clinical Study of Apatinib Combined with Radiation Therapy in Advanced Non-small Cell Lung Cancer Patients with Brain Metastasis
00:00 - 00:00 | Presenter: Xiaqin Zhang
- Abstract
Loading... -
+
P76.32 - Real-World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation Treated with First and Second Generation TKI
00:00 - 00:00 | Presenter: Dalia Isabel Juarez
- Abstract
Loading... -
+
P76.33 - Concurrent EGFR and KRAS Mutations in Lung Adenocarcinoma: A Single Institution Case Series
00:00 - 00:00 | Presenter: Mahir Khan
- Abstract
Loading... -
+
P76.34 - Exosomal miRNAs Participate in Osimertinib Resistance Mainly Through Bypass Activation Mechanisms in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Tangfeng Lv
- Abstract
Loading... -
+
P76.35 - Genomic Characristic and Prognosis of Concomitant with EGFR Copy Numbers Variations in EGFR Mutated Lung Cancer Patients
00:00 - 00:00 | Presenter: Jiuwei Cui
- Abstract
Loading... -
+
P76.36 - A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Juan Li
- Abstract
Loading... -
+
P76.37 - Comprehensive Investigation of Uncommon EGFR Mutations in 14,429 Chinese Lung Cancer Patients
00:00 - 00:00 | Presenter: Yuzhi An
- Abstract
Loading... -
+
P76.38 - Afatinib as a Potential Therapeutic Option for Non-small Cell Lung Cancer Patients with EGFR G724S
00:00 - 00:00 | Presenter: Hongyun Zhao
- Abstract
Loading... -
+
P76.39 - Acquired Resistance Mechanisms in T790M-Positive Advanced NSCLC Tested by Non-Invasive Molecular Testing (NIMT) and Their Clinical Relevance
00:00 - 00:00 | Presenter: Piyakarn Watcharenwong
- Abstract
Loading... -
+
P76.40 - Molecular Characteristics and Response to EGFR TKIs of EGFR L747 Position Mutation in Lung Cancer Patients.
00:00 - 00:00 | Presenter: Wenfeng Fang
- Abstract
Loading... -
+
P76.41 - Detection of Diverse EGFR c-terminal Truncations (C-trunc) and Sensitivity to Tyrosine Kinase Inhibitors (TKIs) in the Clinic
00:00 - 00:00 | Presenter: Christine M. Lovly
- Abstract
Loading... -
+
P76.42 - OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX
00:00 - 00:00 | Presenter: Josefa Terrasa
- Abstract
Loading... -
+
P76.44 - Application of Longitudinal Exposure-Response Modelling to Support Dacomitinib Starting Dose in Patients with EGFR Mutation-Positive NSCLC
00:00 - 00:00 | Presenter: Weiwei Tan
- Abstract
Loading... -
+
P76.45 - Evolution of Epidermal Growth Factor Receptor (EGFR) Gene Mutations in EGFR-TKIs Treated Chinese NSCLC
00:00 - 00:00 | Presenter: Xin Yu
- Abstract
Loading... -
+
P76.46 - First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
00:00 - 00:00 | Presenter: Wan-Ling Tan
- Abstract
Loading... -
+
P76.47 - Molecular Characteristics and Response to Diverse EGFR TKIs of NSCLC Patients Harboring EGFR E709-T710delinsX
00:00 - 00:00 | Presenter: Wenfeng Fang
- Abstract
Loading... -
+
P76.48 - A CT-Based Radiomic Feature Predicts EGFR Mutation and Response to Targeted Therapy in NSCLC
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P76.49 - The Impact of Baseline Systemic Inflammatory Status Parameters in Patients Treated with EGFR-Tyrosine Kinase Inhibitors
00:00 - 00:00 | Presenter: Petra Martin
- Abstract
Loading... -
+
P76.50 - Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure
00:00 - 00:00 | Presenter: Yu Feng
- Abstract
Loading... -
+
P76.51 - ERβ1 Expression Patterns have Different Effects on EGFR TKIs Treatment Response in EGFR Mutant Lung Adenocarcinoma.
00:00 - 00:00 | Presenter: Zhenxiang Li
- Abstract
Loading... -
+
P76.52 - Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC
00:00 - 00:00 | Presenter: Alessandro Leonetti
- Abstract
Loading... -
+
P76.53 - Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors
00:00 - 00:00 | Presenter: Taihei Ono
- Abstract
Loading... -
+
P76.54 - Prognostic Value of Radiotherapy Pattern for Late-Stage Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinomas
00:00 - 00:00 | Presenter: Zhenxiang Li
- Abstract
Loading... -
+
P76.55 - Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
00:00 - 00:00 | Presenter: Satoshi Igawa
- Abstract
Loading... -
+
P76.56 - High PD-L1 Expression is Aassociated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
00:00 - 00:00 | Presenter: Seung Hyeun Lee
- Abstract
Loading... -
+
P76.57 - Resistance Mechanisms to Osimertinib Upon it’s Line of Therapy in Patients with EGFR+ NSCLC and Beyond
00:00 - 00:00 | Presenter: Vered Fuchs
- Abstract
Loading... -
+
P76.58 - Osimertinib for EGFR-Positive NSCLC Patients with Leptomeningeal Metastases Harboring T790M-Positive or T790M-Negative Mutations
00:00 - 00:00 | Presenter: Haiyan Xu
- Abstract
Loading... -
+
P76.59 - Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
00:00 - 00:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P76.60 - FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading... -
+
P76.61 - Long Follow up Study of Comparing Erlotinib (ER) with Gefitinib (GE) for Previously Treated Advanced Non-Small Cell Lung Cancer: WJOG5108LFS
00:00 - 00:00 | Presenter: Ryo Toyozawa
- Abstract
Loading... -
+
P76.62 - RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC
00:00 - 00:00 | Presenter: Andreas N Saltos
- Abstract
Loading... -
+
P76.63 - Dacomitinib Induces a Drastic Response in Metastatic Brain Lesions of Patients with EGFR-mutant Non-small-cell Lung Cancer: A Brief Report
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P76.64 - Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)
00:00 - 00:00 | Presenter: Benjamin Solomon
- Abstract
Loading... -
+
P76.65 - CNS Efficacy of AST2818 in Patients with T790M-Positive Advanced NSCLC: Data from a Phase I-II Dose-Expansion Study
00:00 - 00:00 | Presenter: Yuankai Shi
- Abstract
Loading... -
+
P76.66 - Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC
00:00 - 00:00 | Presenter: Jorge Nieva
- Abstract
Loading... -
+
P76.67 - Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
00:00 - 00:00 | Presenter: Adam Pluzanski
- Abstract
Loading... -
+
P76.68 - The Impact of Eligibility for Anti-Angiogenic Treatment to the Prognosis of Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
00:00 - 00:00 | Presenter: Hiroaki Kodama
- Abstract
Loading... -
+
P76.69 - Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US
00:00 - 00:00 | Presenter: Lauren Bartolome
- Abstract
Loading... -
+
P76.70 - Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Jacqueline V. Aredo
- Abstract
Loading... -
+
P76.71 - RYK Confers Drug Tolerance to Osimertinib in Lung Cancer Cells with EGFR Mutations
00:00 - 00:00 | Presenter: Shuta Ohara
- Abstract
Loading... -
+
P76.72 - A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases
00:00 - 00:00 | Presenter: Simon Ekman
- Abstract
Loading... -
+
P76.73 - MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
00:00 - 00:00 | Presenter: S. Martin Shreeve
- Abstract
Loading... -
+
P76.74 - PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC
00:00 - 00:00 | Presenter: Trishala Agrawal
- Abstract
Loading... -
+
P76.75 - Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Kiran Munawar
- Abstract
Loading... -
+
P76.76 - EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer and the Role of Diabetes Mellitus and Metformin
00:00 - 00:00 | Presenter: Élia Rodrigues Cipriano
- Abstract
Loading... -
+
P76.77 - Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
00:00 - 00:00 | Presenter: Weineng Feng
- Abstract
Loading... -
+
P76.78 - Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading... -
+
P76.79 - Osimertinib in Poor PS Patients with T790M-Positive Advanced NSCLC after Progression of EGFR TKI Treatments (NEJ032B)
00:00 - 00:00 | Presenter: Ryota Saito
- Abstract
Loading... -
+
P76.80 - The Role of Surgical Resection of Advanced Non-Small Cell Lung Cancer after a Response to EGFR-TKI
00:00 - 00:00 | Presenter: Po-Lan Su
- Abstract
Loading... -
+
P76.81 - Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma harboring EGFR–RAD51 Fusion: A Brief Report
00:00 - 00:00 | Presenter: Han-Min Wang
- Abstract
Loading... -
+
P76.82 - Osimertinib versus First-Generation EGFR-TKIs in Untreated EGFR-Mutant NSCLC with Brain Metastasis: 362 Real-World Cases
00:00 - 00:00 | Presenter: Jianjiao Ni
- Abstract
Loading... -
+
P76.83 - Brain Metastasis from Lung Cancers - Intermittent High Dose Afatinib as a Palliative Salvage Therapy for EGFR+ NSCLC.
00:00 - 00:00 | Presenter: Jo Monsen
- Abstract
Loading... -
+
P76.84 - EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
00:00 - 00:00 | Presenter: Maisha T Chowdhury
- Abstract
Loading... -
+
P76.85 - Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
00:00 - 00:00 | Presenter: Sukhmani K. Padda
- Abstract
Loading... -
+
P76.87 - Efficacy of Dacomitinib in EGFR TKI Refractory Metastatic Non-Small Cell Lung Cancer (EGFR Mutant) with Leptomeningeal Metastases
00:00 - 00:00 | Presenter: Daniel Chan
- Abstract
Loading... -
+
P76.88 - Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs
00:00 - 00:00 | Presenter: Jun Ma
- Abstract
Loading... -
+
P76.89 - Is it Possible to Halt Cachexia in Poor Performance Patients with Metastatic EGFR Positive Lung Cancer?
00:00 - 00:00 | Presenter: Zhuang Yao Boh
- Abstract
Loading... -
+
P76.90 - Molecular Characteristics of BRAF Mutations in EGFR Mutant NSCLC after Progression on EGFR TKIs and Response to Combination Targeted Therapy
00:00 - 00:00 | Presenter: Wenfeng Fang
- Abstract
Loading... -
+
P76.91 - Analysis of P53 Lysine-Encoding Mutations Reveals a Relationship Between Codon 132 Mutations and EGFR Mutations in Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Jing Zhang
- Abstract
Loading... -
+
P76.92 - TKI and Intrathoracic Perfusion in First-line Stage IV Lung Adenocarcinoma with EGFR Mutation and Malignant Pleural Effusion
00:00 - 00:00 | Presenter: Weijia Huang
- Abstract
Loading... -
+
P76.93 - The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P76.94 - Survival Analyses and Molecular Predictors of Outcomes in Patients Treated with Osimertinib for Metastatic NSCLC Harboring EGFR Mutation
00:00 - 00:00 | Presenter: Danilo Giffoni M. M. Mata
- Abstract
Loading... -
+
P76.95 - Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Kai-Cheng Peng
- Abstract
Loading... -
+
P76.96 - START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm+ Advanced NSCLC
00:00 - 00:00 | Presenter: Jianying Zhou
- Abstract
Loading... -
+
P76.97 - Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis
00:00 - 00:00 | Presenter: DEZHI Cheng
- Abstract
Loading... -
+
P76.98 - NSCLC Patients With Rare EGFR Mutations in Exons 18 and 19 Benefits From Treatment With EGFR Tyrosine Kinase Inhibitors
00:00 - 00:00 | Presenter: Junying Xu
- Abstract
Loading... -
+
P76.99 - Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
00:00 - 00:00 | Presenter: Dongqing Lv
- Abstract
Loading...
-
+
P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P77.01 - Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC
00:00 - 00:00 | Presenter: John Wrangle
- Abstract
Loading... -
+
P77.02 - Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
P77.03 - A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
P77.04 - PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading... -
+
P77.05 - Phase II Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC After Progression on First-Line Therapy: BTCRC-LUN15-017
00:00 - 00:00 | Presenter: Emily Sisel
- Abstract
Loading...
-
+
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P78.01 - Nivolumab in Second Line Non-Small Cell Lung Cancer – Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057
00:00 - 00:00 | Presenter: Sanjay Popat
- Abstract
Loading... -
+
P78.02 - A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non–Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Chang Liu
- Abstract
Loading... -
+
P78.03 - Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
00:00 - 00:00 | Presenter: Cheng Huang
- Abstract
Loading... -
+
P78.04 - Efficacy and Safety Analysis of Atezolizumab Monotherapy in Patients With Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Kazutoshi Komiya
- Abstract
Loading... -
+
P78.05 - Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome
00:00 - 00:00 | Presenter: Cameron Champion Wood
- Abstract
Loading... -
+
P78.06 - Dynamic Risk Prediction for Disease Control With Nivolumab in Advanced or Recurrent Non-Small Cell Lung Cancer Patients (NewEpoch)
00:00 - 00:00 | Presenter: Tomoya Fukui
- Abstract
Loading... -
+
P78.07 - High Grade Toxicity and Response to PD-1 Axis Inhibitors in Advanced NSCLC
00:00 - 00:00 | Presenter: Mor Moskovitz
- Abstract
Loading... -
+
P78.08 - Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland
00:00 - 00:00 | Presenter: Magdalena Knetki-Wróblewska
- Abstract
Loading... -
+
P78.09 - Immunotherapy Beyond Progression for Patients with Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jinliang Wang
- Abstract
Loading... -
+
P78.10 - Immunotherapy in Non-Small Cell Lung Cancer with High PD-L1 Expression and Coexistent RET- Fusion: The Description of Two Cases.
00:00 - 00:00 | Presenter: Magdalena Knetki-Wróblewska
- Abstract
Loading... -
+
P78.11 - Immunotherapy-Induced Coeliac Disease in the Curative Lung Cancer Patient on Adjuvant Durvalumab
00:00 - 00:00 | Presenter: Samantha Rae Hopkins (Maiden Name Kestenbaum)
- Abstract
Loading... -
+
P78.12 - A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer
00:00 - 00:00 | Presenter: Domenico Galetta
- Abstract
Loading... -
+
P78.13 - Real-World Outcomes After Immunotherapy in NSCLCa: The Experience of the Oncology Center of Hospital Moinhos De Vento.
00:00 - 00:00 | Presenter: Fernando Castilho Venero
- Abstract
Loading... -
+
P78.14 - The Efficacy and Safety of ICIs in Treating Postoperative Recurrence of NSCLC: Results of Two Hospitals in Japan
00:00 - 00:00 | Presenter: Yuriko Yagi
- Abstract
Loading... -
+
P78.15 - Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
00:00 - 00:00 | Presenter: Cristina Julian
- Abstract
Loading... -
+
P78.16 - Real-World Outcomes of Camrelizumab (SHR-1210) in Treating Advanced Non-Small Cell Lung Cancer: A Multicenter Prospective Study
00:00 - 00:00 | Presenter: Kangsheng Gu
- Abstract
Loading...
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P79.01 - TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezolizumab with Chemoradiation (AFT-16)
00:00 - 00:00 | Presenter: Woo Yul Byun
- Abstract
Loading... -
+
P79.02 - Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
P79.03 - A Phase 3 Study of the PD-1 Inhibitor Retifanlimab (INCMGA00012) Plus Platinum-Based Chemotherapy in 1L mNSCLC: POD1UM-304
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P79.04 - A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis.
00:00 - 00:00 | Presenter: Dwight H Owen
- Abstract
Loading... -
+
P79.05 - Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Caroline Huynh
- Abstract
Loading... -
+
P79.06 - CHIO3: ChEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer (AFT-46)
00:00 - 00:00 | Presenter: Linda W Martin
- Abstract
Loading... -
+
P79.07 - Comparative Efficacy and Safety of PD-(L)1 Inhibitors Combined with 1st-Line Chemotherapy for Advanced NSCLC: A Meta-Analysis
00:00 - 00:00 | Presenter: Alessandro Di Federico
- Abstract
Loading... -
+
P79.08 - Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P79.09 - Neoadjuvant Combination Sintilimab plus Chemotherapy in Patients with Resectable Stage IIIA Non-Small Cell Lung Cancer.
00:00 - 00:00 | Presenter: Kewei Ma
- Abstract
Loading...
-
+
P80 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy/ Immunotherapy Plus Targeted Therapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P80.01 - A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC
00:00 - 00:00 | Presenter: Baohui Han
- Abstract
Loading...
first
prev
